FRM
FATE icon

Fox Run Management’s Fate Therapeutics FATE Stock Holding History

Fox Run Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,000
Closed -$25.4K – 814
2023
Q3 		$25.4K Buy
+12,000
New +$39.8K 0.01% 664
2023
Q1 		– Sell
-18,551
Closed -$187K – 745
2022
Q4 		$187K Buy
+18,551
New +$348K 0.08% 497
2018
Q2 		– Sell
-12,268
Closed -$120K – 743
2018
Q1 		$120K Buy
+12,268
New +$118K 0.03% 672

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Fox Run Management's FATE Position: Q4 2023 in Review

Fox Run Management sold out of Fate Therapeutics (FATE) in Q4 2023, closing a stake of 12,000 shares — an estimated $25.4K sold.

Fox Run Management first reported a position in FATE in Q1 2018 and held it in 3 quarters. The position peaked at $187K in Q4 2022. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

  • Fox Run Management reported no remaining Fate Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Fox Run Management sold 12,000 Fate Therapeutics shares in Q4 2023, an estimated $25.4K.
  • Fox Run Management first reported a position in Fate Therapeutics in Q1 2018 and held it in 3 quarters.
  • Fox Run Management's Fate Therapeutics position peaked at $187K in Q4 2022.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on Fox Run Management's 13F filing for Q4 2023, filed 13 Feb 2024.